- Report
- June 2022
- 257 Pages
Global
From €2332EUR$2,625USD£2,010GBP
€4665EUR$5,250USD£4,021GBP
- Report
- June 2022
- 177 Pages
Global
From €2332EUR$2,625USD£2,010GBP
€4665EUR$5,250USD£4,021GBP
- Report
- May 2022
- 170 Pages
Middle East
From €2332EUR$2,625USD£2,010GBP
€4665EUR$5,250USD£4,021GBP
- Report
- March 2022
- 182 Pages
Global
From €2332EUR$2,625USD£2,010GBP
€4665EUR$5,250USD£4,021GBP
- Report
- March 2022
- 273 Pages
Global
From €2332EUR$2,625USD£2,010GBP
€4665EUR$5,250USD£4,021GBP
- Report
- November 2021
- 261 Pages
Global
From €2332EUR$2,625USD£2,010GBP
€4665EUR$5,250USD£4,021GBP
- Report
- June 2023
- 186 Pages
Global
From €4132EUR$4,650USD£3,561GBP
- Report
- September 2023
- 168 Pages
Global
From €5287EUR$5,950USD£4,557GBP
- Report
- March 2023
- 150 Pages
Global
From €5287EUR$5,950USD£4,557GBP
- Report
- January 2024
- 94 Pages
United States
From €5287EUR$5,950USD£4,557GBP
- Report
- September 2023
- 190 Pages
Global
From €2213EUR$2,490USD£1,907GBP
- Report
- January 2023
- 165 Pages
Global
From €2221EUR$2,500USD£1,915GBP
- Report
- January 2024
- 257 Pages
Global
From €4443EUR$5,000USD£3,829GBP
- Report
- March 2023
- 356 Pages
Global
From €4443EUR$5,000USD£3,829GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3110EUR$3,500USD£2,681GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3110EUR$3,500USD£2,681GBP
- Report
- September 2024
- 82 Pages
Japan
From €3110EUR$3,500USD£2,681GBP
- Report
- August 2024
- 130 Pages
North America
From €3554EUR$4,000USD£3,063GBP
- Report
- April 2024
- 185 Pages
Global
From €3999EUR$4,500USD£3,446GBP
- Report
- November 2022
- 111 Pages
Global
From €3999EUR$4,500USD£3,446GBP

Prostate cancer is a type of cancer that affects the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is the most common cancer in men in the United States, and the second most common cause of cancer death in men. Prostate cancer is typically treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments.
The prostate cancer market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to benefit from the introduction of novel therapies, such as immunotherapies and targeted therapies, which are expected to improve the prognosis of patients. Additionally, the increasing focus on early diagnosis and the development of new diagnostic tools are expected to drive the market growth.
Some of the key players in the prostate cancer market include AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more